Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: Gastrointestinal stromal tumors

Cancer Genetics and Cytogenetics

Volumn 135, Issue 1, 2002, Pages 1-22

  Sandberg, Avery A ^a   Bridge, Julia A ^b  

^a ST JOSEPH'S HOSPITAL AND MEDICAL CENTER   (United States)

^b NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BONE TUMOR; CLINICAL FEATURE; CYTOGENETICS; GASTROINTESTINAL TUMOR; GENE MUTATION; HISTOPATHOLOGY; HUMAN; LEIOMYOMA; LEIOMYOSARCOMA; MOLECULAR GENETICS; MYOSARCOMA; PRIORITY JOURNAL; REVIEW; SOFT TISSUE TUMOR; TUMOR SUPPRESSOR GENE; ARTICLE; CANCER DIAGNOSIS; CARCINOGENESIS; CHROMOSOME TRANSLOCATION; DESMOPLASTIC SMALL ROUND CELL TUMOR; FLUORESCENCE IN SITU HYBRIDIZATION; KARYOTYPING; MALIGNANT TRANSFORMATION;

BONE NEOPLASMS; CARCINOMA, SMALL CELL; CHROMOSOME ABERRATIONS; CYTOGENETIC ANALYSIS; FIBROMA, DESMOPLASTIC; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; SOFT TISSUE NEOPLASMS;

EID: 0036806406     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-4608(02)00546-0     Document Type: Article

References (246)

1. Neuroectodermal differentiation of the gastrointestinal tumors in the Carney triad. An ultrastructural and immunohistochemical study
2. CD34 expression in stromal tumors of the gastrointestinal tract
3. Gastrointestinal pacemaker cell tumor (GIPACT). Gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal
4. Embryonic form of smooth muscle myosin heavy chain (SMemb/MHC-B) in gastrointestinal stromal tumor and interstitial cells of Cajal
5. Interstitial cells of Cajal as precursors of gastrointestinal stromal tumors
6. Gastrointestinal stromal tumors may originate from a subset of CD34-positive interstitial cells of Cajal
7. Gastrointestinal stromal tumor, uncommitted type, with monosomies 14 and 22 as the only chromosomal abnormalities
8. Evaluation of the safety and efficacy of an oral molecularly-targeted therapy, STI571, in patients (Pts) with unresectable or metastatic gastrointestinal stromal tumors (GISTS) expressing C-KIT (CD117)
9. Effect of the tyrosine kinase inhibitor STI571 in a patient with gastrointestinal stromal tumor
10. Researchers optimistic about sea change treatment
11. STI 571, an active drug in metastatic gastrointestinal stromal tumors (GIST), an EORTC phase I study
12. Molecular insights into the histogenesis and pathogenesis of gastrointestinal stromal tumors
13. Gastrointestinal Stromal Tumor Workshop
14. Gastrointestinal stromal tumours; an update
15. Gastrointestinal stromal tumors; Recent advances in understanding their biology
16. Immunohistochemical spectrum of GISTs at different sites and their differential diagnosis with a reference to CD117 (KIT)
17. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors
18. Gastrointestinal stromal tumors
19. Smooth muscle tumors of the gastrointestinal tract and retroperitoneal tissues
20. Bizarre smooth muscle tumors of the stomach
21. Tumeurs myoides intra-murales de l'estomac-considerations microseopiques a propos de 6 cas
22. Subclassification of gastrointestinal stromal tumors based on evaluation by electron microscopy and immunohistochemistry
23. Gastrointestinal stromal tumors
24. Gastrointestinal stromal tumors in the appendix. A clinicopathologic and immunohistochemical study of four cases
25. The histopathological differential diagnosis of gastrointestinal stromal tumors
26. A clinicopathologic and immunohistochemical study of gastrointestinal stromal tumors
27. Smooth muscle tumors of the gastrointestinal tract; Analysis of prognostic factors
28. Two hundred gastrointestinal stromal tumors. Recurrence patterns and prognostic factors for survival
29. Mesenchymal tumors of the gastrointestinal tract; A paradise for acronyms (STUMP, GIST, GANT, and now GIPACT), implication of the c-kit in genesis, and yet another of the many emerging roles of the interstitial cells of Cajal in the pathogenesis of gastrointestinal diseases?
30. Gastrointestinal stromal tumors, intramural leiomyomas, and leiomyosarcomas in the rectum and anus. A clinicopathologic, immunohistochemical, and molecular genetic study of 144 cases
31. Mesenchymal tumors of muscularis mucosae of colon and rectum are benign leiomyomas that should be separated from gastrointestinal stromal tumors-clinicopathologic and immunohistochemical study of eighty-eight cases
32. Gastrointestinal stromal tumor versus intra-abdominal fibromatosis of the bowel wall; A clinically significant differential diagnosis
33. Cause of familial and multiple gastrointestinal autonomic nerve tumors with hyperplasia and interstitial cells of Cajal is germline mutation of the c-kit gene
34. Neoplastic and pre-neoplastic changes in gastrointestinal endometriosis. A study of 17 cases
35. Small intestinal stromal tumors with skeinoid fibers. Clinicopathological, immunohistochemical, and ultrastructural investigations
36. Gastrointestinal stromal tumors and leiomyosarcomas in the codon. A clinicopathologic, immunohistochemical, and molecular genetic study of 44 cases
37. Prognosis and surveillance of gastrointestinal stromal/smooth muscle tumors
38. Differentiation of diminutive and partially myoid gut stromal tumors
39. Schwannomas in the colon and rectum. A clinicopathologic and immunohistochemical study of 20 cases
40. Benign schwannoma of the gastrointestinal tract; A clinicopathologic and immunohistochemical study
41. CD117; A sensitive marker for gastrointestinal stromal tumors that is more specific than CD34
42. CD34 expression by gastrointestinal tract stromal tumors
43. Gastric schwannoma-a clinicopathological analysis of six cases
44. CD34. A review
45. Multiple gastrointestinal tumors arising from the interstitial cells of Cajal (ICCs)-a potential association with neurofibromatosis type 1 (NF1)
46. Solitary solid stromal gastrointestinal tumors in von Recklinghausen's disease with minimal smooth muscle differentiation
47. Auerbach's myenteric plexus. A possible site of origin for gastrointestinal stromal tumors in von Recklinghausen's neurofibromatosis
48. Gastrointestinal autonomic nerve tumor. Immunohistochemical and molecular identity with gastrointestinal stromal tumor
49. Gastrointestinal autonomic nerve (GANT) tumor. Ultrastructural evidence for a newly recognized entity
50. Gastrointestinal stromal tumours; an immunohistochemical study of 165 cases
51. Gastrointestinal stromal tumours; correlation of immunophenotype with clinicopathological features
52. Cell markers in gastrointestinal stromal tumors
53. Cytomorphology of gastrointestinal stromal tumor; diagnostic role of aspiration cytology, core biopsy and immunochemistry
54. Analysis of KIT mutation and protein expression in fine needle aspirates of gastrointestinal stromal/smooth muscle tumors
55. c-kit protein (CD117) localization in myenteric ganglion cells (MGC) of the human gastrointestinal tract
56. Diagnosis of gastrointestinal stromal tumor by fine-needle aspiration biopsy; a cytological and immunological study
57. Gain-of-function of c-kit in human gastrointestinal stromal tumors
58. Sur les ganglions et plexus nerveux de l'intestin
59. Interstitial cells of Cajal; intestinal pacemaker cells?
60. Congenital interstitial cell of Cajal hyperplasia with neuronal intestinal dysplasia
61. Developmental origin and Kit-dependent development of the interstitial cells of Cajal in the mammalian small intestine
62. A case for interstitial cells of Cajal as pacemakers and mediators of neurotransmission in the gastrointestinal tract
63. Interstitial cells of Cajal generate a rhythmic pacemaker current
64. Blockade of Kit signaling induces transdifferentiation of interstitial cells of Cajal to a smooth muscle phenotype
65. Requirement of c-kit for development of intestinal pacemaker system
66. W/kit gene required for interstitial cells of Cajal and for intestinal pacemaker activity
67. Stem cell factor is encoded at the Sl locus of the mouse and is the ligand for the c-kit tyrosine kinase receptor
68. Mutation of the proto-oncogene c-kit blocks development of interstitial cells and electrical rhythmicity in murine intestine
69. c-kit-dependent development of interstitial cells and electrical activity in the murine gastrointestinal tract
70. Cellular and molecular basis for electric rhythmicity in gastrointestinal muscles
71. Origin of the c-kit positive interstitial cells in the avian bowel
72. Origin of interstitial cells of Cajal in the mouse intestine
73. Calponin and h-caldesmon in soft tissue tumors; Consistent h-caldesmon immunoreactivity in gastrointestinal stromal tumors indicates traits of smooth muscle differentiation
74. CD117 (c-kit); A sensitive and specific marker for gastrointestinal stromal tumors (GISTs)
75. Familial multiple gastrointestinal stromal tumours with associated abnormalities of the myenteric plexus layer and skeinoid fibres
76. The proto-oncogene c-kit and c-kit ligand in human disease
77. Human proto- ncogene c-kit; a new cells surface receptor tyrosine kinase for an unidentified ligand
78. Identification of a ligand for the c-kit proto-oncogene
79. Preferential localization of c-kit product in tissue mast cells, basal cells of skin, epithelial cells of breast, small cell lung carcinoma and seminoma/dysgerminoma in human; immunohistochemical study on formalin-fixed, paraffin-embedded tissues
80. Growth factor receptor tyrosine kinases
81. Primary structure of c-kit; relationship with the CSF-1/PDGF receptor kinase family-oncogenic activation of v-kit involves deletion of extracellular domain and C terminus
82. Structure of the receptor for platelet-derived growth factor helps define a family of closely related growth factor receptors
83. Structural alteration of viral homologue of receptor proto-oncogene fms at carboxyl terminus
84. Primary structure and functional expression of rat and human stem cell factor DNAs
85. The hematopoietic growth factor KL is encoded by the Sl locus and is the ligand of the c-kit receptor, the gene product of the W locus
86. From white spots to stem cells; the role of the Kit receptor in mammalian development
87. Molecular pathology of c-kit proto-oncogene and development of gastrointestinal stromal tumors
88. Signal transduction by allosteric receptor oligomerization
89. Substrate phosphorylation specificity of the human c-kit receptor tyrosine kinase
90. c-kit tyrosine kinase activity and substrate interaction
91. A specific combination of substrates is involved in signal transduction by the kit-encoded receptor
92. Signal transduction by normal isosforms and W mutant variants of the Kit receptor tyrosine kinase
93. The Steel/W transduction pathway; kit autophosphorylation and its association with a unique subset of cytoplasmic signaling proteins is induced by the Steel factor
94. cDNA cloning of a novel 85 kd protein that has SH2 domains and regulated binding of PI3-kinase to the PDGT β-receptor
95. A phosphatidylinositol-3 kinase binds to platelet-derived growth factor receptors through a specific receptor sequence containing phosphotyrosine
96. c-src complexes, and PI3-kinase
97. Cloning of PI3 kinase-associated p85 utilizing a novel method for expression/cloning of target proteins for receptor tyrosine kinases
98. Decrease of mast cells in W/Wv mice and their increase by bone marrow transplantation
99. Decreased production of mast cells in S1/S1d anemic mice
100. Hereditary anemia of the mouse; A review for geneticists
101. Disturbed intestinal movement, bile reflux to the stomach, and deficiency of c-kit-expressing cells in Ws/Ws mutant rats
102. Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product
103. Ligand-independent activation of c-kit receptor tyrosine kinase in a murine mastocytoma cell line P-815 generated by a point mutation
104. Substitution of an aspartic acid results in constitutive activation of c-kit receptor tyrosine kinase in a rat tumor mast cell line RBL-2H3
105. Constitutive activation of c-kit in FMA3 murine mastocytoma cells caused by deletion of seven amino acids at the juxtamembrane domain
106. c-kit point mutation of extracellular domain in patients with myeloproliferative disorders
107. A novel gain-of-function of c-kit gene in gastrointestinal stromal tumors
108. Activating c-kit gene mutations in human germ cell tumors
109. c-kit as part of a cell type characteristic multimeric signalling complex
110. Gastrointestinal pacemaker cell tumor-a manifestation of neurofibromatosis type 1 (NF1)
111. c-KIT receptor expression in cutaneous malignant melanoma and benign melanocytic naevi
112. Proto-oncogene c-kit expression in malignant melanoma; Protein loss with tumor progression
113. Expression of the c-kit protein in human solid tumors and in corresponding fetal and adult normal tissues
114. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder
115. Somatic c-KIT activating mutations in urticaria pigmentosa and aggressive mastocytosis; establishment of clonality in a human mast cell neoplasm
116. Biological and clinical review of stromal tumors in the gastrointestinal tract
117. KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors
118. Gain-of-function mutation at the extracellular domain of KIT in gastrointestinal stromal tumours
119. Germline-activating mutation in the kinase domain of KIT gene in familial gastrointestinal stromal tumors
120. Mutations in exons 9 and 13 of KIT gene are rare events in gastrointestinal stromal tumors. A study of 200 cases
121. KIT mutation portends poor prognosis in gastrointestinal stromal/smooth muscle tumors
122. Mutations in exon 11 of c-Kit occur preferentially in malignant versus benign gastrointestinal stromal tumors and do not occur in leiomyomas or leiomyosarcomas
123. Mutations in exon 11 of c-kit occur preferentially in malignant vs. benign gastrointestinal stromal tumors (GISTs)
124. Specific mutation in exon 11 of c-kit proto-oncogene in a malignant gastrointestinal stromal tumor of the rectum
125. Mutations of c-kit mutation on prognosis of gastrointestinal stromal tumors
126. Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors
127. The spectrum of c-kit domain mutations in gastrointestinal stromal tumors (GISTs)
128. KIT gene mutations in gastrointestinal stromal tumors (GIST); lack of clinical correlation
129. Familial gastrointestinal stromal tumours with germline mutation of the KIT gene
130. Congenital gastrointestinal stromal tumour is morphologically indistinguishable from the adult form, but does not express CD117 and carries a favourable prognosis
131. Familial gastrointestinal stromal tumor with hyperpigmentation; association with a germline mutation of the c-kit gene
132. Gastrointestinal stroma tumor of the rectum with activating mutation of c-kit; report of a case
133. Correlation of c-kit mutational status with c-kit protein expression in gastrointestinal stromal tumors
134. Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors
135. Gastrointestinal stromal tumors/smooth tumors (GISTs) in the omentum and mesentery-clinicopathologic and immunohistochemical study of 26 cases
136. KIT mutation portends poor prognosis in gastrointestinal stromal/smooth muscle tumors
137. Growth stimulation of colorectal carcinoma cells via the c-kit receptor is inhibited by TGF-beta 1
138. Soluble c-kit proteins and antireceptor monoclonal antibodies confine the binding site of the stem cell factor
139. KIT gene mutations are not causing the malignant behavior of gastrointestinal stromal tumors
140. The complexity of KIT gene mutations and chromosome rearrangements and their clinical correlation in gastrointestinal stromal (pacemaker cell) tumors
141. KIT signal transduction
142. Alternate splicing creates two forms of the human kit protein
143. Clark SC, Crosier KE. Expression of isoforms of the human receptor tyrosine kinase c-kit in leukemic cell lines and acute myeloid leukemia
144. Expression of the Kit and Kit A receptor isoforms in human acute myelogenous leukemia
145. Isoforms of c-KIT differ in activation of signalling pathways and transformation of NIH3T3 fibroblasts
146. Extragastrointestinal (soft tissue) stromal tumors; an analysis of 48 cases with emphasis on histologic predictors of outcome
147. Does chromosome investigation discriminate between benign and malignant gastrointestinal leiomyomatous tumors?
148. Cytogenetic and morphologic characteristics of gastrointestinal stromal tumors. Recurrent rearrangement of chromosome 1 and losses of chromosomes 14 and 22 as common anomalies
149. Two cases of low-grade gastric leiomyosarcoma with monosomy 14 as the only change
150. Loss of 14q and 22q in gastrointestinal pacemaker cell tumors (GIPACTs)
151. Loss of 14q and 22q in gastrointestinal stromal tumors (pacemaker cell tumors)
152. Chromosomal aberrations in malignant gastrointestinal stromal tumors; correlation with c-KIT gene mutation
153. Loss of heterozygosity on chromosome 1 in gastrointestinal stromal/smooth muscle tumors; Implications of pathogenesis and prognosis
154. Recurrent chromosome aberrations in abdominal smooth muscle tumors
155. DNA copy number losses in chromosome 14; an early change in gastrointestinal stromal tumors
156. Different patterns of DNA copy number changes in gastrointestinal stromal tumors, leiomyomas, and schwan- nomas
157. Allelic loss of 14q and 22q, NF2 mutation, and genetic instability occur independently of c-kit mutation in gastrointestinal stromal tumor
158. Cytogenetic findings in malignant peripheral nerve sheath tumors
159. Cytogenetic and histologic correlation of peripheral nerve sheath tumors of soft tissue
160. Gastrointestinal stromal in an XYY/XY male
161. Numerical chromosomal changes in gastrointestinal stromal tumors (GISTs) by interphase FISH
162. A cytogenetic and FISH analysis of chromosome 14q deletions in 39 gastrointestinal stromal tumors (GISTs)
163. Optimizing comparative genomic hybridization for analysis of DNA-sequence-copy-number changes in solid tumors
164. Comparative genomic hybridization; A new tool in cancer pathology
165. Prognostic DNA sequence copy number changes in stromal tumors of the gastrointestinal tract. 8th International Workshop on Chromosomes & Solid Tumors
166. DNA copy number changes in development and progression in leiomyosarcomas in soft tissues
167. High-resolution deletion mapping of chromosome 14 in stromal tumors of the gastrointestinal tract suggests two distinct tumor suppressor loci
168. Comparative genomic hybridization study on pooled DNAs from tumors of one clinical-pathological entity
169. Loss of heterozygosity at 1p36 predicts poor prognosis of gastrointestinal stromal/smooth muscle tumors
170. DNA sequence copy number changes in gastrointestinal stromal tumors; Tumor progression and prognostic significance
171. Putative chromosomal deletions of 9p, 9q and 22q occur preferentially in malignant gastrointestinal stromal tumors
172. Consistent DNA losses on the short arm of chromosome 1 in a series of malignant gastrointestinal stromal tumors
173. Chromosomal aberrations of malignant gastrointestinal stromal tumors (GIST) detected by CGH
174. + cells in human intestine are fibroblasts adjacent to, but distinct from, interstitial cells of Cajal
175. Gastrointestinal stromal tumors with KIT mutations exhibit a remarkably homogeneous gene expression profile
176. Immunohistochemical staining for KIT (CD117) in soft tissue sarcomas is very limited in distribution
177. Are desmoid tumors KIT positive?
178. Authors' reply to M. Miettinen's letter to the editor
179. The metastatic ability of Ewing's sarcoma cells is modulated by stem cell factor and by its receptor c-kit
180. c-kit is expressed in soft tissue sarcoma of neuroectodermic origin and its ligand prevents apoptosis of neoplastic cells
181. New challenges in the identificaiton of gastrointestinal stromal tumors and other possible KIT-driven tumors
182. Enforced c-KIT expression renders highly metastatic human melanoma cells susceptible to stem cell factor-induced apoptosis and inhibits their tumorigenic and metastatic potential
183. Loss of AP-2 results and downregulation of c-KIT and enhancement of melanoma tumorigenicity and metastasis
184. Gastrointestinal stromal tumors-value of CD34 antigen in their identification and separation from true leiomyomas and schwannomas
185. CD34 immunoexpression in stromal tumours of the gastrointestinal tract and in mesenteric fibromatoses
186. CD34 positivity in fibrosarcomas which arise in dermatofibrosarcoma protuberans
187. Expression of c-kit (CS117) and Ki67 provides information about the possible cell of origin and clinical course of gastrointestinal stromal tumours
188. Prognostic value of proliferating cell nuclear antigen index in gastric stromal tumors
189. Predicting metastatic risk of gastrointestinal stromal tumors; Role of cell proliferation and cell cycle regulatory proteins
190. Differentiation and risk assessment of gastrointestinal stromal tumors
191. Prognosis of gastrointestinal smooth-muscle (stromal) tumors. Dependence on anatomic site
192. Soft tissue leiomyosarcomas and malignant gastrointestinal stromal tumors; differences in clinical outcome and expression of multidrug resistance proteins
193. Colorectal smooth-muscle tumors; A pathologic study with immunohistochemistry and histomorphometry
194. Muscle differentiation and clinicopathologic features of gastrointestinal stromal tumors
195. Expression of smooth muscle-specific proteins in myoepithelium and stromal myofibroblasts of normal and malignant human breast tissue
196. Caldesmon
197. Gastrointestinal stromal tumors-definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis
198. Apoptosis, bcl-2 expression, and p53 expression in gastrointestinal stromal/smooth muscle tumors
199. Telomerase activity and expression hTRT and hTR in gastrointestinal stromal tumors in comparison with extra gastrointestinal sarcomas
200. Expression of transforming growth factor-α and epidermal growth factor receptor in gastrointestinal stromal tumours
201. Stromal tumors of the anorectum. A clinicopathologic study of 22 cases
202. KIT mutation in gastrointestinal stromal/smooth muscle tumors; Dependence on anatomic site
203. Prognostic significance of MIB-1 proliferative index in gastrointestinal stromal tumors
204. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours; a phase I study
205. Response to metastic gastrointestinal stromal tumor including CNS involvement to imatinib mesylate (STI-571)
206. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-Kit and platelet-derived growth factor receptors
207. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome
208. Indolinone tyrosine kinase inhibitors block Kit activation and growth of small cell lung cancer cells
209. STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein; biological and clinical implications
210. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia
211. STI571 revolution; can the newer targeted drugs measure up?
212. The BCR gene and Philadelphia chromosome-positive leukemogenesis
213. CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins
214. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor
215. Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571
216. Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemia
217. C-Kit (CD117) reactivity in extramedullary myeloid tumor/granulocytic sarcoma
218. Gastric stromal tumors (GIST); Correlation of features with aggressive clinical behavior
219. c-kit mutations in gastrointestinal stromal tumors (GISTS)
220. Growth inhibition in dermatofibrosarcoma protuberans tumors by the platelet-derived growth factor receptor antagonist STI571 through induction of apoptosis
221. G-band analyses of a human intestinal leiomyosarcoma
222. Chromosome changes in soft tissue sarcomas
223. t(10;17) as the sole chromosome change in a uterine leiomyosarcoma
224. Consistent chromosome changes in leiomyosarcoma
225. Three possible cytogenetic subgroups of leiomyosarcoma
226. Cytogenetic observations in a human gastric leiomyosarcoma
227. Chromosomal analysis and the classification of soft tissue sarcomas
228. Frequent clonal chromosomal changes in human non-malignant tumors
229. Ring (13)(p11q34) as the sole abnormality in a leiomyosarcoma of the small bowel
230. Chromosomal abnormalities in leiomyosarcomas
231. c-kit mutations in gastrointestinal stromal tumors occur preferentially in the spindle rather than in the epithelioid cell variant
232. Association of KIT exon 9 mutuations in non-gastric primary site and size, and loack of prognostic impact of KIT exon 11 mutations. A clinicopathologic and molecular study of 84 gastrointestinal stromal tumors (GIST)
233. A retrospective immunohistochemical analysis of cases diagnosed as intra-abdominal/retroperitoneal 'leiomyosarcoma' (IA/R LMS); the prevalence of potentially treatable KIT-positive extragastrointestinal stromal tumors (EGIST)
234. Intraepithelial lymphocytosis in small bowel biopsies with normal villus architecture
235. Updates on cytogenetics and molecular genetics of bone and soft tissue tumors; Ewing sarcoma and peripheral primitive neuroectodermal tumors
236. CD99 is expressed by GISTs with neural differentiation and high mitotic index
237. Gastrointestinal stromal tumors involving the liver
238. Is the incidence of secondary neoplasia increased in patients with gastrointestinal stromal tumors (GIST)?
239. β-Catenin immunohistochemistry separates mesenteric fibromatosis from gastrointestinal stromal tumor and sclerosing mesenteritis
240. Biological and clinical significance of cytogenetic abnormalities in low-risk and high-risk gastrointestinal stromal tumors
241. Malignant stromal tumor of the gallbladder with interstitial cells of Cajal phenotype
242. Expression of KIT (CD117) in angiomyolipoma